Twist Bioscience Corp

CRISPR Therapeutics

Recursion Pharmaceuticals

Veracyte

Natera

CareDx

Adaptive Biotechnologies

Guardant Health Inc

Beam Therapeutics

Schrodinger 

ARK Genomic Revolution Multi-Sector ETF

ARKG is an actively managed fund that targets companies involved in the genomics industry.

Genomics has long been one of the more tech-centric corners of the healthcare space, and that remains the case today. That's a strong indication that disruptive technologies often intersect with and depend on one another.

In Genomics, Tech Matters

ARK Fintech Innovation ETF

ARK Innovation ETF

ARK Web x.0 ETF

Disruptive technology-related exchange traded funds rallied on Tuesday as U.S. markets turned risk-on, following positive updates on Russia and Ukraine's negotiations. Among the best-performing non-leveraged ETFs of Tuesday, the ARK Innovation Fund (NYSEArca: ARKK) increased 7.0%, the ARK Web x.0 ETF (NYSEArca: ARKW) advanced 5.9%, the ARK Genomic Revolution Multi-Sector Fund (NYSEArca: ARKG) gained 7.0%, and the [.

Disruptive Tech ETFs Rally on Encouraging Dialogue Between Russia and Ukraine

ARKG has shown better performance over its peers. ARKG has done a overhaul of its portfolio to curb down volatility.

ARKG: Be Patient And Look For A Longer Time Horizon

Global X Robotics & Artificial Intelligence ETF

These funds focus on revolutions in healthcare and technology.

Invest in Next-Gen Technologies With These 2 ETFs

Healthcare innovation equities are languishing, but it could time for one of the most well-known names in the group to turn around, and that could be constructive for select exchange traded funds, including the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG). In a note to clients on Friday, Goldman Sachs analyst Cindy Motz initiated coverage [.

Teladoc Endorsement Could Be Positive for This ETF

Catherine Wood (Trades, Portfolio) (Trades, Portfolio) is a growth stock investor who believes innovation and technology are the keys to great investing returns. Her flagship fund, the Ark Innovation ETF ( ARKK , Financial), focuses on four main pillars:

Ark is Sinking - Will Ark Invest Recover?

ARK Industrial Innovation ETF

While disruptive innovation strategies may experience short-term volatility, ARK's research shows that maintaining a long-term investment time horizon is critical for investors searching for potential returns. Innovation solves problems, and it is expected to transform human lives at an accelerated rate during the next five to 10 years.

Volatility Is Not a Bad Word With a Long-Term Time Horizon

Global X Telemedicine & Digital Health ETF

Emerging Markets Internet & Ecommerce ETF

iShares MSCI USA ESG Optimized ETF

Amplify Mobile Payments ETF

Global X Lithium & Battery Tech ETF

In 2022, the U.S. equities market got off to its worst start to a year since the dark days of the financial crisis, with many areas of the market, including stocks and stock exchange-traded funds (ETFs), selling off. As a result, many investors are rethinking how to position their portfolio for the months ahead.

7 Megatrend Stock ETFs With Massive Potential

With biotechnology stocks, particularly those in mid- and small-cap territory, heavily out of favor at the moment, it's not surprising that some investors are ignoring genomics assets. That sentiment belies what's still one of the most compelling long-term opportunity sets in the healthcare sector.

A Bright Outlook for Gene Editing Investing

Every night, an email comes out from Ark Investment Management highlighting the stocks that were bought or sold by the firm's ETFs. In recent months, the emails have been known to cause certain stocks to spike in the after-hours session.

Cathie Wood Explains Why Ark Investment Sends A Daily Email Disclosing Stock Moves

Experienced healthcare and biotechnology investors know that January brings the arrival of the widely followed JPMorgan healthcare conference. This year, it's taking place in virtual fashion, but that's not preventing the event from stoking the usual chatter and optimism directed at specific corners of the biotechnology space.

Gene Editing Stocks Might Be Building Some Momentum

It's just one deal, but genomics companies with exposure to in vivo gene editing may be getting a much-needed boost after blue-chip pharmaceuticals company Pfizer (NYSE:PFE) announced a related agreement with Beam Therapeutics (NASDAQ:BEAM) on Monday. Among exchange traded funds with leverage to the accord is the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG).

Pfizer/Beam Deal Highlights In Vivo Potential

Cathie Wood's multibillion-dollar funds are off to a rocky start in 2022.

Yield Spikes Muddy ARK's Waters

ARK Transparency ETF

Two of ARK Invest's most popular ETFs were down double digits in 2021. Is it time to buy?

Should You Bet on Cathie Wood in 2022?

The 3D Printing ETF

Let's take a look at how ARK Invest ETFs performed in 2021.

How Did Cathie Wood's ARK Invest Perform in 2021?

Clustered regularly interspaced short palindromic repeats, colloquially known as CRISPR, is one of the bedrocks of the genomics investment thesis, and it could be poised for big things in 2022. If that's the case, exchange traded funds, namely the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG), could stand out.

CRISPR Could Come Alive in 2022

From an investment perspective, adequately tapping rapidly emerging healthcare evolution requires flexibility. Among exchange traded funds, the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) answers that call.

Genomics Could Make Inroads in Prenatal Testing

Global X Genomics & Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Wisdomtree BioRevolution Fund

These ETFs give you exposure to CRISPR gene editing without having to pick individual stocks.

Top ETFs Tracking CRISPR Gene Editing

Genomics equities are scuffling alongside the broader biotechnology space this year, but that doesn't diminish the long-term disruptive attributes of genomics investments. With genomics ranking as one of the prime pillars of innovative growth investing going forward, this year's slump could represent opportunity with exchange traded funds such as the ARK Genomic Revolution Multi-Sector Fund [.

Unusual Sequencing Could Be Predictive in Coronavirus Fight

ARKG historically outperformed in its category based on high early valuation in many of its holdings.

ARK Genomic ETF: Likely Economic Victim With Low Institutional Interest

For investors who don't want to pick specific stocks, ARKG could be a good way to invest in biotech.

Is Cathie Wood's Genomic ETF a Buy After Sinking This Year?

Key innovations supporting the investment thesis are long-read sequencing and gene-editing. Short-term underperformance may reverse in the near term according to trend indicators.

ARKG: Reversal Of Downtrend

ARKG provides exposure to the high growth areas of gene therapy, bio-informatics, bio-inspired computing, and molecular medicine.

ARKG: This Strategy Comes With High Risks

Ark Invest boss Cathie Wood's year has gone from bad to worse in December, with the flagship ARKK ETF tumbling 10%.

Cathie Wood's nightmarish 2021: Ark Innovation has plunged 24% as tech has crashed, with 6 out of 8 Ark funds in the red

The emergence of the Omicron variant of the coronavirus carries myriad implications for data collection, healthcare innovation, and science, among other fields. There are investment implications as well, including for genomics assets.

News for ARK Genomic Revolution Multi-Sector ETF ETF (ARKG)